Iga Nephropathy
📧 Sign up to get email alerts when something new happens for Iga Nephropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases [EARLY_Phase 1]
An early Phase 1 clinical study evaluating the safety and efficacy of GT719 universal cell injection for immune-mediated kidney diseases is …
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease [Phase 2]
Phase 2 clinical trial evaluating ADX-038 for complement-mediated kidney disease, including IgA nephropathy and C3 glomerulopathy, is curren…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition [Phase 3]
A Phase 3 clinical trial evaluating mezagitamab for adults with primary IgA nephropathy is currently recruiting to evaluate safety and effic…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Phase 2 Study of JADE101 in Participants With Immunoglobulin A Nephropathy [Phase 2]
A Phase 2 study of JADE101 for IgA nephropathy is listed, but the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression [Phase 3]
Phase 3 clinical trial update announcing ongoing recruitment for Sefaxersen (RO7434656) in adults with high-risk primary IgA nephropathy.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
An ongoing biomarker evaluation study for IgA nephropathy and other glomerular diseases is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Monthly Dosing of Atacicept in IgAN [Phase 2]
A Phase 2 trial of atacicept for IgA nephropathy is ongoing but not currently recruiting, per Vera Therapeutics' update.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) [Phase 2]
This clinical trial update reports a Phase 2 study of NM8074 for IgA nephropathy, which is currently not yet recruiting.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Study of WAL0921 in Patients With Glomerular Kidney Diseases [Phase 2]
Walden Biosciences reports a Phase 2 clinical trial of WAL0921 in multiple glomerular diseases, currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease [EARLY_Phase 1]
An early-phase trial of allogeneic CD19/BCMA CAR-T therapy for B-cell–related autoimmune diseases is recruiting at The Children's Hospital o…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study of Zigakibart in Adults With IgA Nephropathy [Phase 3]
A Phase 3 clinical trial update indicates Zigakibart is being studied in adults with IgA nephropathy and the study is currently active but n…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN [Phase 3]
Phase 3 pediatric trial evaluating atrasentan for efficacy, pharmacokinetics, safety and tolerability in primary IgA nephropathy; the study …
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: FXS6837 for the Treatment of IgAN Patients [Phase 2]
Phase 2 clinical trial of FXS6837 for IgA nephropathy is listed as not yet recruiting, with Shanghai Fosun Pharmaceutical as sponsor.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study of YKST02 in Participants With Primary IgA Nephropathy [EARLY_Phase 1]
A clinical trial update for the drug YKST02 in participants with primary IgA nephropathy; the early-phase 1 study is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Study of ARO-CFB in Adult Healthy Volunteers [Phase 1]
Phase 1 study of ARO-CFB in healthy adult volunteers for an IgA Nephropathy program; the trial is currently active but not recruiting, spons…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: PS-002 for the Treatment of IgA Nephropathy in Adults [Phase 1, Phase 2]
This clinical trial update indicates PS-002 for immunoglobulin A nephropathy is in Phase 1/Phase 2 and currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection
A clinical trial update describing primary-data collection on treatment experience for IgA nephropathy patients treated with iptacopan and/o…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Study of Ravulizumab in Pediatric Participants With Primary IgAN [Phase 3]
Phase 3 clinical trial update indicates Ravulizumab is being studied in pediatric participants with primary IgA nephropathy, including IgA v…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Efficacy and Safety Study of HS-10542 for IgA Nephropathy [Phase 2]
Phase 2 clinical trial update for HS-10542 in IgA nephropathy, with the study currently not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy [Phase 3]
This clinical trial update describes a rollover extension program to evaluate the long-term safety and tolerability of open-label iptacopan …
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN [Phase 3]
A Phase III clinical trial to evaluate the efficacy and safety of HSK39297 tablet in adults with primary IgA nephropathy is currently recrui…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy [Phase 4]
This document discusses a Phase 4 trial evaluating extended TARPEYO treatment beyond 9 months in adults with primary IgA nephropathy. The st…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease [Phase 1]
Phase 1 clinical trial update for a CAR T-cell therapy targeting CD19 and BCMA in autoimmune conditions, with recruiting status and potentia…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Managed Access Programs for EXV811, Atrasentan
This release describes managed access programs for EXV811 (Atrasentan) in IgA nephropathy, provided by Novartis to eligible patients outside…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: A Study of SHR-2173 in Participants With Primary IgA Nephropathy [Phase 2]
This entry provides a Phase 2 clinical trial update for SHR-2173 in primary IgA nephropathy, with the study not yet recruiting.